MP6-02 LOCATION OF DISEASE DOES NOT IMPACT PCA3'S ABILITY TO PREDICT CANCER ON BIOPSY

Abstract

You have accessJournal of UrologyProstate Cancer: Markers II1 Apr 2015MP6-02 LOCATION OF DISEASE DOES NOT IMPACT PCA3'S ABILITY TO PREDICT CANCER ON BIOPSY Padraic O'Malley, Bashir Al Hussein Al Awamlh, Daniel P. Nguyen, Martin G. Sanda, Ian M. Thompson, John T. Wei, Richard Lee, Mark A. Rubin, Christopher E. Barbieri, Michael P. Hermann, and Douglas S. Scherr Padraic O'MalleyPadraic O'Malley More articles by this author , Bashir Al Hussein Al AwamlhBashir Al Hussein Al Awamlh More articles by this author , Daniel P. NguyenDaniel P. Nguyen More articles by this author , Martin G. SandaMartin G. Sanda More articles by this author , Ian M. ThompsonIan M. Thompson More articles by this author , John T. WeiJohn T. Wei More articles by this author , Richard LeeRichard Lee More articles by this author , Mark A. RubinMark A. Rubin More articles by this author , Christopher E. BarbieriChristopher E. Barbieri More articles by this author , Michael P. HermannMichael P. Hermann More articles by this author , and Douglas S. ScherrDouglas S. Scherr More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.249AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Urine testing for prostate cancer antigen 3 (PCA3) has been utilized to improve stratification of patients into high or low risk for occult tumors after previous negative biopsy. Many of these tumors are thought to be those under-sampled by traditional biopsy methods, in particular anterior and apical (AnA) lesions. The current study examined the ability of PCA3 to predict prostate cancer in varying locations. METHODS Prospective post-DRE urine was collected at three academic centers from 572 men presenting for traditional, non-targeted, trans-rectal ultrasound biopsy as part of the Early Detection Research Network (EDRN) study. Patients were stratified into three groups: 1) No cancer (NC), 2) AnA, and 3) non-AnA (nAnA). Patients with involvement of both AnA and nAnA were excluded. Outcomes examined included PCA3 score for all, clinically significant (CS; >Gleason 7) lesions, and NC controls. Statistical analyses used included the Shapiro-Wilk, ANOVA, and Mann-Whitney U. Receiver operating characteristics (ROC) curves were generated and the area under the curve (AUC) was obtained for PCA3 as a predictor of positive biopsy RESULTS 572 men had complete demographic and biopsy site information. Amongst all study patients, age and PSA were no different between the three groups (Table 1). Prostate cancer prevention trial (PCPT) risk calculator score, PCPT high risk score, and PCA3 were found to be significantly different for AnA and nAnA groups compared to NC (Table 1). The AUC for ROC curves predicting positive biopsy for the AnA and nAnA groups were 0.69 (95% CI, 0.61-0.76) and 0.72 (95% CI, 0.66-0.77) respectively (p<0.001). Men with CS disease (AnA n=21, nAnA n=68), had significant differences between AnA and nAnA groups compared to NC for PCPT, PCPT HR, and PCA3 scores. The AUC for ROC curves for the AnA and nAnA groups were 0.78 (95% CI, 0.69-0.87) and 0.74 (95% CI, 0.67-0.81), respectively (p<0.001; Table 1). CONCLUSIONS Although PCA3 is approved for use in stratifying the cancer risk in men who may have lesions under-sampled by traditional biopsy methods, its variation with location has not been studied to date. PCA3 can serve as an effective predictor of disease regardless of anatomic location. Its utility only increases for detection of clinically significant disease in these traditionally under-sampled areas. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e54 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Padraic O'Malley More articles by this author Bashir Al Hussein Al Awamlh More articles by this author Daniel P. Nguyen More articles by this author Martin G. Sanda More articles by this author Ian M. Thompson More articles by this author John T. Wei More articles by this author Richard Lee More articles by this author Mark A. Rubin More articles by this author Christopher E. Barbieri More articles by this author Michael P. Hermann More articles by this author Douglas S. Scherr More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...